Soligenix announced extended top line results from its Phase 2a clinical trial of SGX302 in patients with mild-to-moderate psoriasis, highlighting clinical improvements with an optimized gel formulation of the investigational therapy. The findings underscore the potential of SGX302 as a noncarcinogenic, photodynamic treatment for this chronic skin condition that affects millions worldwide.
The Phase 2a trial progressed into an extension cohort that enrolled an additional four patients treated with an improved topical gel formulation of SGX302. According to the company, SGX302 was well tolerated by all patients in cohort 3, with no drug-related adverse events identified during the treatment period. The optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application compared to previous versions.
SGX302 utilizes visible light-activated synthetic hypericin, representing a first-in-class photodynamic therapy mechanism. This approach differs significantly from conventional psoriasis treatments that often carry risks of carcinogenicity or other serious side effects. The therapy was applied to psoriasis lesions twice a week over an 18-week period, mirroring the duration used in prior study cohorts.
The importance of these findings lies in the potential to address significant unmet medical needs in psoriasis treatment. Current therapies, including phototherapy with ultraviolet light and various systemic medications, often present safety concerns or limited long-term efficacy. SGX302's novel mechanism offers a different therapeutic approach that could provide patients with a safer alternative, particularly for those who cannot tolerate existing treatments or require long-term management of their condition.
For the pharmaceutical industry, successful development of SGX302 could establish a new category of photodynamic therapies for dermatological conditions. The technology's application might extend beyond psoriasis to other skin disorders where targeted, non-systemic treatments are needed. The company's focus on rare diseases with unmet medical needs aligns with growing regulatory and market emphasis on specialized therapeutics.
The latest news and updates relating to Soligenix are available in the company's newsroom at https://ibn.fm/SNGX. BioMedWire, which distributed the announcement, is a specialized communications platform focusing on biotechnology and biomedical sciences developments within the Dynamic Brand Portfolio at IBN that delivers various distribution services including access to wire solutions and social media distribution to millions of followers. More information about their services is available at https://www.BioMedWire.com, with full terms of use and disclaimers accessible at https://www.BioMedWire.com/Disclaimer.
These extended results represent an important milestone in the development of SGX302, providing additional safety data and formulation improvements that could support further clinical advancement. As psoriasis remains a chronic condition requiring long-term management, new treatment options with favorable safety profiles could significantly impact patient quality of life and treatment adherence. The continued development of SGX302 demonstrates ongoing innovation in dermatological therapeutics aimed at balancing efficacy with patient safety.
